Clearpoint Neuro, Inc. ( (CLPT) ) has released its Q4 earnings. Here is a breakdown of the information Clearpoint Neuro, Inc. presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ClearPoint Neuro, Inc. is a global company specializing in device, cell, and gene therapy solutions, providing precise navigation for brain and spine procedures, and partnering with pharmaceutical and biotech firms for CNS therapeutic delivery.
In 2024, ClearPoint Neuro achieved record revenue growth of 31% year-over-year, reaching $31.4 million, and significantly reduced its operational cash burn by 35%. The company also expanded its global presence by activating 25 new centers, tripling its historical activation rate.
Key financial highlights include a 76% growth in overall product revenue, driven by the SmartFrame OR platform and ClearPoint Prism Laser Therapy System. The company also fully repaid a $10 million convertible note, leaving it debt-free, and reported a gross margin increase to 61% from 57% the previous year. Operating expenses rose by 8% due to increased personnel costs and R&D investments.
Looking ahead, ClearPoint Neuro anticipates revenue growth between 15% and 31% in 2025, driven by strategic initiatives to expand its drug delivery ecosystem, global footprint, and product offerings. The company aims to support its BioPharma partners through the regulatory process and prepare for the commercialization of cell and gene therapies.